Marinus Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Marinus Pharmaceuticals

11/05/2023 14:32

* Marinus Pharmaceuticals Inc  MRNS.OQ  reported a quarterly
adjusted loss of 67 cents​​ per share for the quarter ended in
March. The mean expectation of eight analysts for the quarter
was for a loss of 72 cents per share.
    * Revenue fell 26.8% to $10.38 million from a year ago;
analysts
expected $5.88 million. 
    * Marinus Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 67 cents​.
    * The mean earnings estimate of analysts had risen by
about 2.5%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * Marinus Pharmaceuticals Inc shares had risen by 38.8% this
quarter and gained 140.7% so far this year.
    * The company reported a quarterly loss of $34.73 million.
    * Wall Street's median 12-month price target for Marinus
Pharmaceuticals Inc is $22.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 10 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
11 at 01:32 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.72          -0.67          Beat
 Dec. 31 2022      -0.70          -0.76          Missed
 Sep. 30 2022      0.47           -0.94          Missed
 Jun. 30 2022      -0.69          -1.06          Missed